<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413243</url>
  </required_header>
  <id_info>
    <org_study_id>TRIOMS-01</org_study_id>
    <nct_id>NCT01413243</nct_id>
  </id_info>
  <brief_title>Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome</brief_title>
  <acronym>TRIOMS</acronym>
  <official_title>Trichuris Suis Ova (TSO)in Recurrent Remittent Multiple Sclerosis and Clinically Isolated Syndrome - A Monocentric, Prospective, Randomized, Double-blind and Placebo-controlled Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trichuris suis ova (TSO) is a probiotic treatment based on the hygiene hypothesis, that has
      proven safe and effective in autoimmune inflammatory bowel disease. Clinical trails indicate
      that helminth infections have an immunomodulatory effect in multiple sclerosis as well.
      Investigators hypothesize that TSO® 2500 eggs given oral every 2 weeks for 12 months is - due
      to its immunomodulatory and antiinflammatory effect - in recurrent remittent multiple
      sclerosis and clinically isolated syndrome significantly more effective than an oral placebo
      treatment as assed by new T2 lesions in cerebral magnetic resonance imaging and clinical
      examination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TSO has an impact on the Th1-Th2 balance and effects Il-10 producing B-cells, mechanisms that
      result in an antiinflammatory effect.

      A 12 month treatmet with TSO is safe and well-tolerated
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative number of new T2 hyperintensive in cerebral magnetic resonance imaging (MRI)</measure>
    <time_frame>after 12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>reduction NAA/Cr-ratio in MR-spectroscopy</measure>
    <time_frame>after 12 month of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new Gadolinium lesions in magnetic resonance imaging (MRI) cerebral magnetic resonance imaging (MRI)</measure>
    <time_frame>after 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new T2 hyperintensive in cerebral magnetic resonance imaging (MRI)</measure>
    <time_frame>after 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapes, proression of diability measured in EDSS (Expanded Disability Status Scale) and MSFC (Multiple Sclerosis Functional Composite),</measure>
    <time_frame>after 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>participants will be followed for the duration of the study and have every 3 month planed visits.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Drug: Trichuris suis ova</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Trichuris suis ova (TSO) 2500 eggs every 2 weeks for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: Placebo, fluid every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trichuris suis ova</intervention_name>
    <description>Trichuris suis ova 2500 eggs every 2 weeks</description>
    <arm_group_label>Drug: Trichuris suis ova</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>TSO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  active Recurrent remittent Multiple Scleosis or Clinically isolated Syndrome

          -  inefficacy or intolerance for a therapy with Interferon-beta

          -  age 18 - 65

          -  EDSS &lt;4

        Exclusion Criteria:

          -  secondary or primary chronic progressive Multiple Sclerosis

          -  Immunomodulatoric or immunosuppressive therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berit Rosche, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité-University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Friedemann Paul, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Charité - University, NeuroCure Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin, Department of Neurology</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2011</study_first_posted>
  <last_update_submitted>May 5, 2016</last_update_submitted>
  <last_update_submitted_qc>May 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Berit Rosche</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Multipe sclerosis, Trichuris suis ova</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

